PT  - JOURNAL ARTICLE
AU  - Sun, Liu
AU  - Wu, Hang-Jing
TI  - The global prevalence and genetic spectrum of primary carnitine deficiency
AID  - 10.1101/2024.05.29.24308100
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.29.24308100
4099  - http://medrxiv.org/content/early/2024/05/31/2024.05.29.24308100.short
4100  - http://medrxiv.org/content/early/2024/05/31/2024.05.29.24308100.full
AB  - Background Primary carnitine deficiency (PCD) is an autosomal recessive rare disorder of carnitine cycle and carnitine transport caused by mutations in the SLC22A5 gene. The prevalence of PCD is unclear. This study aimed to estimate the carrier frequency and genetic prevalence of PCD using Genome Aggregation Database (gnomAD) data.Methods The pathogenicity of SLC22A5 variants was interpreted according to the American College of Medical Genetics and Genomics (ACMG) standards and guidelines. The minor allele frequency (MAF) of SLC22A5 gene disease-causing variants in 807,162 unique individuals was examined to estimate the global prevalence of PCD in five major ethnicities: African (afr), Admixed American (amr), East Asian (eas), Non-Finnish European (nfe) and South Asian (sas). The global and population-specific carrier frequencies and genetic prevalence of PCD were calculated using the Hardy–Weinberg equation.Results In total, 195 pathogenic/likely pathogenic variants (PV/LPV) were identified according to ACMG standards and guidelines. The global carrier frequency and genetic prevalence of PCD were 1/88 and 1/31,260, respectively.Conclusions The prevalence of PCD is estimated to be 1/30,000 globally, with a range of between 1/20,000 and 1/70,000 depending on ethnicity.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthe internal funds from the Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University (18612022) and Yunnan Fundamental Research Projects (Grant No. 202101AU070007).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yesthe Science Data Bank (ScienceDB) repository. https://doi.org/10.57760/sciencedb.09147